October 19, 2016 11:44 AM EDT

Liver tox cases force Daiichi Sankyo to curtail recruitment for PhIII trial of a ‘breakthrough’ drug

John Carroll

Editor & Founder

Two cases of serious liver toxicity forced investigators to suspend enrollment on Daiichi Sankyo’s Phase III program for its “breakthrough” drug pexidartinib (PLX3397). But both …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Liver tox cases force Daiichi Sankyo to curtail recruitment for PhIII trial of a ‘breakthrough’ drug

John Carroll

Editor & Founder

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Liv­er tox cas­es force Dai­ichi Sankyo to cur­tail re­cruit­ment for PhI­II tri­al of a ‘break­through’ drug

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Liver tox cases force Daiichi Sankyo to curtail recruitment for PhIII trial of a ‘breakthrough’ drug

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M